By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lipocine Inc. 

675 Arapeen Drive
Suite 202
Salt Lake City  Utah  84108  U.S.A.
Phone: 801-994-7383 Fax:


Company News
Lipocine Inc. (LPCN)'s Oral Testosterone Well Tolerated In Phase III Study 6/30/2015 7:14:05 AM
Lipocine Inc. (LPCN) To Present At The JMP Securities Life Sciences Conference 6/16/2015 10:50:48 AM
Lipocine Inc. (LPCN) Announces Successful Completion Of Food Effect Study For LPCN 1021, An Oral Testosterone Product Candidate 6/15/2015 9:01:11 AM
Lipocine Inc. (LPCN) Announces Development Plans For LPCN 1107 6/8/2015 7:51:37 AM
Lipocine Inc. (LPCN) Receives FDA Orphan Drug Designation For LPCN 1107, An Oral Product Candidate For The Prevention Of Preterm Birth 6/2/2015 1:28:07 PM
Lipocine Inc. (LPCN) Appoints Dr. Jyrki Mattila As Chief Business Officer 5/18/2015 8:52:26 AM
Lipocine Inc. (LPCN) Announces Presentation Of Additional LPCN 1021 Clinical Data At American Urological Association Annual Meeting 5/11/2015 7:50:34 AM
Lipocine Inc. (LPCN) Announces Completion Of LPCN 1021, Oral Testosterone, Phase III Clinical Trial 4/30/2015 7:21:09 AM
Lipocine Inc. (LPCN) Announces Closing Of $34.8 Million Common Stock Offering 4/30/2015 7:03:12 AM
Lipocine Inc. (LPCN) Prices $30.2 Million Public Offering Of Common Stock 4/30/2015 7:02:27 AM